|Awarded On||November 16, 2016|
|Title||Effective Exploitation Of Structural Data For Oncology|
|Award Mechanism||Individual Investigator Research Awards for Computational Biology|
|Institution/Organization||Texas A&M Engineering Experiment Station|
|Principal Investigator/Program Director||Thomas Ioerger|
|Cancer Sites||All Sites|
Biotechnology and pharmaceutical industries are taking advantage of genomics and proteomics to identify targets in which one protein interacts with another (protein-protein interactions, PPIs); these are pivotal in many aspects of cancer research. It is relatively easy to validate these targets using “biologicals”, typically humanized monoclonal antibodies (hmAbs). As medicines, however, hmAbs can have drawbacks compared with small molecules designed for the same function; in cancer these are associated with delivery of the drug to the core of the tumor, cost, shelf life, and bioavailability. For these reasons, small molecules tend to be preferred over hmAbs as medicines, all other factor...